Extension of ischemic therapeutic time window by a free radical scavenger, Edaravone, reperfused with tPA in rat brain

Neurological Research

Volumn 26, Issue 3, 2004, Pages 342-348

  Zhang, Wenri ^a   Sato, Keiko ^a   Hayashi, Takeshi ^a   Omori, Nobuhiko ^a   Nagano, Isao ^a   Kato, Shinsuke ^b   Horiuchi, Seikoh ^c   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Edaravone; Free radical scavenger; Stroke; Therapeutic time window; tPA

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; NORPHENAZONE; SCAVENGER; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN INFARCTION; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NICK END LABELING; NONHUMAN; RAT; REPERFUSION; STROKE; SURVIVAL RATE;

ALDEHYDES; ANIMALS; ANTIPYRINE; BRAIN ISCHEMIA; CELL COUNT; DEOXYADENOSINES; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; FREE RADICAL SCAVENGERS; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMORRHAGE; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; RATS; RATS, WISTAR; SURVIVAL ANALYSIS; TETRAZOLIUM SALTS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 2442462438     PISSN: 01616412     EISSN: None     Source Type: Journal    
DOI: 10.1179/016164104225014058     Document Type: Article

References (33)

1. ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator in acute hemispheric stroke. J Am Med Ass. 1995; 274: 1017-1025
2. NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-1587
3. Sereghy T, Overgaard K, Boysen G. Neuroprotection by excitatory amino acid antagonist augments the benefit of thrombolysis in embolic stroke in rats. Stroke 1993; 24: 1702-1708
4. Lekieffre D, Benavides J, Scatton B, Nowicki J-P. Neuroprotection afforded by a combination of eliprodil and a thrombolytic agent, rt-PA, in a rat thromboembolic stroke mode. Brain Res 1997; 776: 88-95
5. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. N Engl J Med 1999; 340: 1781-1787
6. Larrue V, von Kummer R del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the ECASS study. Stroke 1999; 28: 957-960
7. NINDS rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous TPA therapy for ischemic stroke. Stroke 1997; 28: 2109-2118
8. Group TNr-PS S. Effect of intravenous rt-PA on ischemic stroke lesion size measured by computed tomography. Stroke 2000; 31: 2912-2919
9. Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001; 21: 2-14
10. Zoppo GJ, Zeumer H, Harker LA. Thrombolytic therapy in stroke: possibilities and hazards. Stroke 1986; 7: 595-607
11. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev 1993; 5: 1-16
12. Abe K, Yuki S, Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger. Stroke 1988; 19: 480-485
13. Watanabe T, Yuki S, Egawa M, Nishi H. protective effect of MCI-186 on cerebral ischemia: Possible involvement of free radical scavenging and antioxidant action. J Pharm Exp Ther 1994; 268: 1597-1604
14. Nishi H, Watanabe T, Sakurai H, Yuki S, Ishibashi A. Effect of MCI-186 on brain edema in rats. Stroke 1989; 20: 1236-1240
15. Oishi R, Itoh Y, Nishibori M, Watanabe T, Nishi H, Saeki K. Effect of MCI-186 on ischemia-induced changes in monoamine metabolism in rat brain. Stroke 1989; 20: 1557-1564
16. Mihaz U, Tanaka M, Tsukamoto H, et al. Effect of MCI-186 on postischemic reperfusion injury in isolated rat heart. Free Rad Res 1996;24: 361-367
17. Watanabe T, Morita I, Nishi H, Murota S. Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostagland Leuk Essent Fatty Acids 1988; 33: 81-87
18. K Abe, T Hayashi. Expression of the glial cell line-derived neurotrophic factor in rat brain after transient MCA occlusion. Brain Res 1997; 776: 230-234
19. T Hayashi, K Abe, Y Itoyama. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab 1998; 18: 887-895
20. Zhang W.R, Kitagawa H, Hayashi T, et al. Topical application of neurotrophin-3 attenuates ischemic brain injury after transient middle cerebral artery occlusion in rats. Brain Res 1999; 842: 211-214
21. Watanabe T, Yuki S, Saito K, Sato S, Sugimoto J, Ohori Y. Pharmacological studies of MCI-186, a new drug for acute stroke. Jpn Pharmacol Ther 1997; 25(Suppl.): 36-38
22. Zhang RL, Zhang ZG, Chopp M, Zivin JA. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999; 30: 624-629
23. Jiang Q, Zhang RL, Zhang ZG, et al. Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke. J Cereb Blood Flow Metab 2000; 20: 21-27
24. Münch G., Thorne J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Rev 1997; 23: 134-143
25. Smith CD, Carney JM, Starke-Reed PE. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci USA 1991; 88: 10540-10543
26. Mecocci P, MacGarvey U, Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 1994; 36: 747-751
27. McCracken E, Valeriani V, Simpson C, Jover T, McCulloch J, Dewar D. The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes. J Cereb Blood Flow Metab 2000; 20: 1529-1536
28. Keller JN, Hanni KB, Markesbery WR. 4-hydroxynonenal increases neuronal susceptibility to oxidative stress. J Neurosci Res 1999; 58: 823-830
29. Zhang L, Zhang ZG, Zhang RL, et al. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32: 2926-2931
30. Andersen M, Overgaard K, Meden P, Boysen G. Effects of citicoline combined with thrombolytic therapy in a rat embolic stroke mode. Stroke 1999; 30: 1464-1471
31. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). J Am Med Ass 1995; 274: 1017-1025
32. Fiorelli M, Bastianello S, von Kummer R, et al. Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. Stroke 1999; 30: 2280-2284
33. Berger C, Fiorelli M, Steiner T, et al. Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic? Stroke 2001; 32: 1330-1335